Lipitor is the biggest-selling prescription drug in history, generating $10.7bn global sales and accounting for 9 per cent of Pfizer’s revenue in 2010. But it is one of five drugs made in Ireland – along with Pfizer’s Enbrel, Takeda’s Actos, Merck’s Singulair and Eli Lilly’s Zyprexa – either about to go off patent or to lose protection in the US within a year, according to an analysis by the Financial Times.
“The patent cliff certainly exists and it is something policymakers need to be aware of. Some commentators estimate the fall in worldwide revenues will be close to €100bn,” says Matt Moran, director of PharmaChemical Ireland, an industry trade body.
Monday, February 27, 2012
Patent losses threaten Irish recovery - FT.com